|
Sign In to gain access to subscriptions and/or personal tools.
|
Non-AT1-receptor-mediated protective effect of angiotensin against acute ischaemic stroke in the gerbil
François Dalmay
Department of Physiology, University Hospital of Limoges, France
Hakim Mazouz
Division of Nephrology, University Hospital of Amiens, France
Julien Allard
Department of Physiology, University Hospital of Limoges, France
Francis Pesteil
Department of Physiology, University Hospital of Limoges, France
Jean Michel Achard
Department of Physiology, University Hospital of Limoges, France
Albert Fournier
Division of Nephrology, University Hospital of Amiens, France, neph{at}chu-amiens.fr
Previous studies have shown that angiotensin II (Ang II), by mediating rapid recruitment of collateral circulation, has a protective effect in the setting of acute ischaemia. In an experimental model of acute cerebral ischaemia in the gerbil, Fernandez et al. have reported that the mechanism of the protective effect of Ang II is blood pressure (BP)-independent,1 and that the AT 1-receptor antagonist, losartan, but not the ACE inhibitor (ACE-I), enalapril, decreases mortality following unilateral carotid artery ligation. 2 The aim of this study was to examine the reproducibility of the respective effects of losartan and enalapril, and to verify that these differential effects are drug class-related. Acute cerebral ischaemia was induced in anaesthetised gerbils by unilateral carotid ligation. The effect of pretreatment with two different ACE-I (enalapril and lisinopril), and two different AT 1-receptor antagonists (losartan and candesartan), administered orally or intravenously, on mortality were compared. Kaplan-Meier survival curves at day three were analysed by a log-rank test. Pretreatment with both enalapril and lisinopril significantly decreased survival at day three compared with controls, while the AT1-receptor antagonists losartan and candesartan, despite similarly lowering BP, did not increase mortality. Coadministration of losartan and enalapril increased mortality to the same extent as enalapril alone. This study confirms that Ang II contributes to protective mechanisms against acute cerebral ischaemia through non AT1-receptor-mediated, BP-independent effects.
Key Words: AT1-receptor • stroke
References
- Fernandez L., Spencer D., Kaczmar T. Angiotensin II decreases mortality rate in gerbils with unilateral carotid ligation. Stroke 1986;17:82-5.[Abstract/Free Full Text]
- Fernandez L., Caride V., Strömberg C., Näveri L., Wicke J. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994;24:937-40.[Web of Science][Medline]
[Order article via Infotrieve]
- Fernandez L., Caride V., Twickler J., Galardy R. Reninangiotensin and development of collateral circulation after renal ischaemia. Am J Physiol 1982;243:H869-75.[Web of Science][Medline]
[Order article via Infotrieve]
- Kaliszewski C., Fernandez L., Wicke J. Differences in mortality rate between abrupt and progressive carotid ligation in the gerbil:role of endogenous angiotensin II. J Cerebral Blood Flow and Metab 1988;8:149-54.
- Svarzbein L., Baez S. On the relationship of brain vasculature to production of neurological deficit and morphological changes following acute unilateral common carotid artery ligation in gerbils. J Neurol Sci 1975;25:75-92.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Blezer EL, Nicolay K., Bar D. et al. Enalapril prevents imminent and reduces manifest cerebral edema in stroke-prone hypertensive rats. Stroke 1998;29(8):1671-7; discussion 1677-8.[Web of Science]
- Lee RM, Wang H., Smeda JS Perindopril treatment in the prevention of stroke in experimental animals. J Hypertens 1996;14(6)(suppl):S29-33. 8. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of angiotensin-converting-enzyme inhibitor on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Engl J Med 2000; 342:145-53.[Abstract/Free Full Text]
- Hansson L., Lindholm L., Niskanen L. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the captopril prevention project (CAPPP). Lancet 1999;353:611-16.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992;304:405-12.[Abstract/Free Full Text]
- Brown M., Brown J. Does angiotensin II protect against strokes? Lancet 1986;ii:427-9.
- MRC trial of treatment of mild hypertension: principal results.Medical Research Council Working Party. Br Med J (Clin Res Ed) 1985;291:97-104.[Medline]
[Order article via Infotrieve]
Journal of Renin-Angiotensin-Aldosterone System, Vol. 2, No. 2,
103-106 (2001)
DOI: 10.3317/jraas.2001.009
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Kobayashi, N. Hirawa, K. Yatsu, Y. Kobayashi, Y. Yamamoto, S. Saka, D. Andoh, Y. Toya, G. Yasuda, and S. Umemura
Relationship between silent brain infarction and chronic kidney disease
Nephrol. Dial. Transplant.,
January 1, 2009;
24(1):
201 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Granger, T. Vowinkel, and T. Petnehazy
Modulation of the Inflammatory Response in Cardiovascular Disease
Hypertension,
May 1, 2004;
43(5):
924 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fournier, F. H. Messerli, J. M. Achard, and L. Fernandez
Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials
J. Am. Coll. Cardiol.,
April 21, 2004;
43(8):
1343 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
